Pedro Eduardo Nascimento Silva Vasconcelos

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

Pedro Eduardo Nascimento Silva Vasconcelos, Carol Gergis, Hollis Viray et al. · JTO Clinical and Research Reports · 2020 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

Differentially expressed plasmatic microRNAs in Brazilian patients with Coronavirus disease 2019 (COVID-19): preliminary results

Aline de Souza Nicoletti, Marília Berlofa Visacri, Carla Regina da Silva Correa da Ronda et al. · Molecular Biology Reports · 2022 · 32 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +15

Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment

Karen Prado Herzer Mattos, Isabela Romão Gouvêa, Júlia C.F. Quintanilha et al. · Journal of Clinical Pharmacy and Therapeutics · 2019 · 25 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

Pedro Eduardo Nascimento Silva Vasconcelos, Ikei S. Kobayashi, Susumu Kobayashi et al. · JTO Clinical and Research Reports · 2020 · 23 citations · Full text

Medicine, Oncology, Pharmacology +12

Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations

Pedro Eduardo Nascimento Silva Vasconcelos, Ikei S. Kobayashi, Susumu Kobayashi et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 20 citations · Full text

Medicine, Oncology, Pharmacology +12